Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

Published - Jul 2019| Analyst - Dr. Cheryl Lee Barton| Code - PHM212A
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Single User License: $995 Member Price: FREE

Report Highlights

The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.

This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.

What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.

Report Includes

  • An introduction to interleukin-2 (IL-2) and identification of its applications
  • Insights into the latest trends and technologies in the IL-2 research and development
  • Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
  • Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent  CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing  a novel oncologic monoclonal antibody that boosts  IL-2 but has an improved side-effect profile
  • Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
  • An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Analyst Credentials

Dr. Cheryl Lee Barton has more than 10 years’ practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report